Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic markers of early response to lurasidone in acute schizophrenia.

The pharmacogenomics journal - 20 Feb 2025

Yoshikawa Akane, Li Jiang, Alliey-Rodriguez Ney, Meltzer Herbert Y

Abstract excerpt

Prediction of treatment response by genetic biomarkers has potential for clinical use and contributes to the understanding of pathophysiology and drug mechanism of action. The purpose of this study is to detect genetic biomarkers possibly associated with response to lurasidone, during the first four weeks of treatment. One-hundred and seventy-one acutely psychotic patients from two placebo-controlled clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Antipsychotic Agents
Share to PTCH1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to SHH gene

Share to Genetic Markers

Share to Polymorphism, Single Nucleotide

Share to Schizophrenia

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39979276
DOI: 10.1038/s41397-024-00360-z
PMCID: PMC11842270

Genes

SHH
GABRB1
PTCH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic markers of early response to lurasidone in acute schizophrenia.PMID 39979276Read ↗

Genetic Markers of Early Response to Lurasidone in Acute SchizophreniaSemantic proximity Read ↗

Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes.Semantic proximity Read ↗

Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials.Semantic proximity Read ↗

Risperidone-induced changes in DNA methylation from peripheral blood in first-episode schizophrenia parallel neuroimaging and cognitive phenotypeSemantic proximity Read ↗

The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.Semantic proximity Read ↗

Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients.Semantic proximity Read ↗

Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes.Semantic proximity Read ↗

Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.Semantic proximity Read ↗

Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.Semantic proximity Read ↗

Risperidone-induced changes in DNA methylation in peripheral blood from first-episode schizophrenia patients parallel changes in neuroimaging and cognitive phenotypes.Semantic proximity Read ↗

Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients.Semantic proximity Read ↗

RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.